The Japanese subsidiary of French pharma major Sanofi (Euronext: SAN) has signed a license agreement with Asahi Kasei Pharma (TYO: 3407) for the marketing of rheumatoid arthritis drug Kevzara Subcutaneous Injection (sarilumab [rDNA origin]) in Japan.
Developed jointly by Sanofi and US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) Kevzara is a human monoclonal antibody that binds to interleukin-6 (IL-6) receptors and thereby blocks the action of interleukin (IL)-6, which is known to play an important role in inflammation of the synovial membrane of joints.
Global peak sales of Kevzara, which was approved and launched in the USA, Canada, and Europe during 2017, are projected at $1 billion-plus a year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze